Table 5. Open in new tab Therapeutic...

	Total	Active SLE	Inactive SLE	P-value^a
First-line treatment
Prednisone introduced or increased	27/37 (73)^b	14 (93)	13/22 (59)^c	0.03
Prednisone, median (IQR), mg/day	20 (3.5–60)	50 (10–60)	20 (0–60)^c	0.09
Intravenous methylprednisolone bolus	16/37 (43)^c	8 (53)	8/22 (36)^c	0.33
Hydroxychloroquine	11/37 (30)^c^,^d	5 (33)	6/22 (27)^c	0.73
Colchicine	3/37 (8)^c	1 (7)	2/22 (9)^c	1
Antihistamines	6/37 (16)^c	1 (7)	5/22 (23)^c	0.37
Immunosuppressive treatment	20/37 (54)^c	11 (73)	9/22 (41)^c	0.09
Rituximab	6/37 (16)^c	2 (13)	4/22 (18)^c	1
Mycophenolate mofetil	6/37 (16)^c^,^e	4 (27)	2/22 (9)^c	0.19
Methotrexate	4/37 (11)^c	2 (13)	2/22 (9)^c	1
Azathioprine	3/37 (8)^c	2 (13)	1/22 (4)^c	0.55
Cyclophosphamide	2/37 (5)^c	1 (7)	1/22 (4)^c	1
Belimumab	1/37 (3)^c	1 (7)	0/22 (0)^c	0.40
Baricitinib	1/37 (3)^c	1 (7)	0/22 (0)^c	0.40

Total

Active SLE

Inactive SLE

P-value^a

(n = 38)

(n = 15)

(n = 23)

First-line treatment

Prednisone introduced or increased

27/37 (73)^b

14 (93)

13/22 (59)^c

0.03

Prednisone, median (IQR), mg/day

20 (3.5–60)

50 (10–60)

20 (0–60)^c

0.09

Intravenous methylprednisolone bolus

16/37 (43)^c

8 (53)

8/22 (36)^c

0.33

Hydroxychloroquine

11/37 (30)^c^,^d

5 (33)

6/22 (27)^c

0.73

Colchicine

3/37 (8)^c

1 (7)

2/22 (9)^c

Antihistamines

6/37 (16)^c

1 (7)

5/22 (23)^c

0.37

Immunosuppressive treatment

20/37 (54)^c

11 (73)

9/22 (41)^c

0.09

Rituximab

6/37 (16)^c

2 (13)

4/22 (18)^c

Mycophenolate mofetil

6/37 (16)^c^,^e

4 (27)

2/22 (9)^c

0.19

Methotrexate

4/37 (11)^c

2 (13)

2/22 (9)^c

Azathioprine

3/37 (8)^c

2 (13)

1/22 (4)^c

0.55

Cyclophosphamide

2/37 (5)^c

1 (7)

1/22 (4)^c

Belimumab

1/37 (3)^c

1 (7)

0/22 (0)^c

0.40

Baricitinib

1/37 (3)^c

1 (7)

0/22 (0)^c

0.40

	Total	Active SLE	Inactive SLE	P-value^a
First-line treatment
Prednisone introduced or increased	27/37 (73)^b	14 (93)	13/22 (59)^c	0.03
Prednisone, median (IQR), mg/day	20 (3.5–60)	50 (10–60)	20 (0–60)^c	0.09
Intravenous methylprednisolone bolus	16/37 (43)^c	8 (53)	8/22 (36)^c	0.33
Hydroxychloroquine	11/37 (30)^c^,^d	5 (33)	6/22 (27)^c	0.73
Colchicine	3/37 (8)^c	1 (7)	2/22 (9)^c	1
Antihistamines	6/37 (16)^c	1 (7)	5/22 (23)^c	0.37
Immunosuppressive treatment	20/37 (54)^c	11 (73)	9/22 (41)^c	0.09
Rituximab	6/37 (16)^c	2 (13)	4/22 (18)^c	1
Mycophenolate mofetil	6/37 (16)^c^,^e	4 (27)	2/22 (9)^c	0.19
Methotrexate	4/37 (11)^c	2 (13)	2/22 (9)^c	1
Azathioprine	3/37 (8)^c	2 (13)	1/22 (4)^c	0.55
Cyclophosphamide	2/37 (5)^c	1 (7)	1/22 (4)^c	1
Belimumab	1/37 (3)^c	1 (7)	0/22 (0)^c	0.40
Baricitinib	1/37 (3)^c	1 (7)	0/22 (0)^c	0.40

Table 5.

Open in new tab

Therapeutic management of CV in SLE patients

	Total	Active SLE	Inactive SLE	P-value^a
	(n = 38)	(n = 15)	(n = 23)	P-value^a
First-line treatment
Prednisone introduced or increased	27/37 (73)^b	14 (93)	13/22 (59)^c	0.03
Prednisone, median (IQR), mg/day	20 (3.5–60)	50 (10–60)	20 (0–60)^c	0.09
Intravenous methylprednisolone bolus	16/37 (43)^c	8 (53)	8/22 (36)^c	0.33
Hydroxychloroquine	11/37 (30)^c^,^d	5 (33)	6/22 (27)^c	0.73
Colchicine	3/37 (8)^c	1 (7)	2/22 (9)^c	1
Antihistamines	6/37 (16)^c	1 (7)	5/22 (23)^c	0.37
Immunosuppressive treatment	20/37 (54)^c	11 (73)	9/22 (41)^c	0.09
Rituximab	6/37 (16)^c	2 (13)	4/22 (18)^c	1
Mycophenolate mofetil	6/37 (16)^c^,^e	4 (27)	2/22 (9)^c	0.19
Methotrexate	4/37 (11)^c	2 (13)	2/22 (9)^c	1
Azathioprine	3/37 (8)^c	2 (13)	1/22 (4)^c	0.55
Cyclophosphamide	2/37 (5)^c	1 (7)	1/22 (4)^c	1
Belimumab	1/37 (3)^c	1 (7)	0/22 (0)^c	0.40
Baricitinib	1/37 (3)^c	1 (7)	0/22 (0)^c	0.40

	Total	Active SLE	Inactive SLE	P-value^a
	(n = 38)	(n = 15)	(n = 23)	P-value^a
First-line treatment
Prednisone introduced or increased	27/37 (73)^b	14 (93)	13/22 (59)^c	0.03
Prednisone, median (IQR), mg/day	20 (3.5–60)	50 (10–60)	20 (0–60)^c	0.09
Intravenous methylprednisolone bolus	16/37 (43)^c	8 (53)	8/22 (36)^c	0.33
Hydroxychloroquine	11/37 (30)^c^,^d	5 (33)	6/22 (27)^c	0.73
Colchicine	3/37 (8)^c	1 (7)	2/22 (9)^c	1
Antihistamines	6/37 (16)^c	1 (7)	5/22 (23)^c	0.37
Immunosuppressive treatment	20/37 (54)^c	11 (73)	9/22 (41)^c	0.09
Rituximab	6/37 (16)^c	2 (13)	4/22 (18)^c	1
Mycophenolate mofetil	6/37 (16)^c^,^e	4 (27)	2/22 (9)^c	0.19
Methotrexate	4/37 (11)^c	2 (13)	2/22 (9)^c	1
Azathioprine	3/37 (8)^c	2 (13)	1/22 (4)^c	0.55
Cyclophosphamide	2/37 (5)^c	1 (7)	1/22 (4)^c	1
Belimumab	1/37 (3)^c	1 (7)	0/22 (0)^c	0.40
Baricitinib	1/37 (3)^c	1 (7)	0/22 (0)^c	0.40

Data are n (%), unless stated otherwise. Active SLE was defined according to SELENA-SLEDAI score ≥ 6 after excluding the vasculitis item.

Comparing active SLE to inactive SLE patient.

Prednisone introduction or increase was associated with immunosuppressant treatment (excluding antimalarials and colchicine) in 17.

Positive/number of patients evaluated.

Nine patients had a diagnosis of SLE simultaneously with CV and two had previously diagnosed SLE but undetectable HCQ blood concentration despite a prescription and were therefore considered not receiving HCQ. All but one received another treatment in addition to hydroxychloroquine.

Two patients received rituximab followed by mycophenolate mofetil. One received cyclophosphamide followed by mycophenolate mofetil. Variables with P < 0.05 on univariate analysis are highlighted in bold. IQR: interquartile range.

This Feature Is Available To Subscribers Only